Generic Name and Formulations:
Loteprednol etabonate 0.5%; oph susp; contains benzalkonium chloride.
Bausch & Lomb Inc.
Indications for LOTEMAX:
Steroid-responsive ocular diseases. Post-op inflammation after ocular surgery.
Steroid-responsive diseases: 1–2 drops into affected eye(s) 4 times daily. May give up to 1 drop every 1 hr within the 1st week of therapy. Post-op: 1–2 drops into operated eye(s) 4 times daily beginning 24 hrs after surgery, continue for 2 wks post-op.
Ocular fungal, viral, or mycobacterial infections.
Reevaluate if no improvement after 2 days. Prescribe initially and renew after 14 days only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Soft contact lenses (remove during therapy). Pregnancy (Cat.C). Nursing mothers.
Local reactions (eg, blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation. May delay healing and increase bleb formation after cataract surgery; also, Oint/Gel: anterior chamber inflammation, conjunctival hyperemia, corneal edema, eye pain.
Susp—5mL, 10mL, 15mL, Oint—3.5g; Gel—5g
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Effects of a Low-Carbohydrate Diet on Weight Loss Maintenance
- Sleep Quality in Women With Surgical vs Natural Menopause
- Unhealthy Lifestyle and Rotating Night Shifts Put Nurses at Higher Risk for T2D
- Serious Adverse Events Linked to SGLT2 Inhibitors
- Endocrine-Disrupting Chemicals in Personal Care Products Linked to Early Puberty
- History of Partner Violence Tied to Menopause Symptoms
- Patients Commonly Withhold Medically Relevant Information From Clinicians
- "Gender Panic" in Clinical Settings: Protecting Public Accommodations Access for Transgender Individuals